MCID: LRG016
MIFTS: 30

Large Intestine Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Large Intestine Adenocarcinoma

MalaCards integrated aliases for Large Intestine Adenocarcinoma:

Name: Large Intestine Adenocarcinoma 12 15
Adenocarcinoma of Large Intestine 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050913
UMLS 73 C1319315

Summaries for Large Intestine Adenocarcinoma

Disease Ontology : 12 A large intestine cancer that has material basis in epithelial cells of glandular origin.

MalaCards based summary : Large Intestine Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to cystic basal cell carcinoma and seminal vesicle adenocarcinoma. An important gene associated with Large Intestine Adenocarcinoma is KRT20 (Keratin 20), and among its related pathways/superpathways are Endometrial cancer and Development EGFR signaling pathway. The drugs Iron and Ferric Compounds have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and colon, and related phenotypes are Reduced mammosphere formation and cellular

Related Diseases for Large Intestine Adenocarcinoma

Diseases in the Large Intestine Adenocarcinoma family:

Small Intestine Adenocarcinoma

Diseases related to Large Intestine Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 137)
# Related Disease Score Top Affiliating Genes
1 cystic basal cell carcinoma 10.2 KRT20 KRT7
2 seminal vesicle adenocarcinoma 10.2 KRT20 KRT7
3 transverse colon cancer 10.2 KRT20 KRT7
4 appendix adenocarcinoma 10.2 KRT20 KRT7
5 malignant syringoma 10.2 KRT20 KRT7
6 glandular cystitis 10.2 KRT20 KRT7
7 papillary transitional carcinoma 10.2 KRT20 KRT7
8 eyelid carcinoma 10.2 KRT20 KRT7
9 krukenberg carcinoma 10.2 KRT20 KRT7
10 small cell carcinoma of the bladder 10.2 KRT20 KRT7
11 small cell carcinoma 10.2 KRT20 KRT7
12 intratubular embryonal carcinoma 10.2 KRT20 KRT7
13 bile duct cystadenocarcinoma 10.2 KRT20 KRT7
14 bile duct adenoma 10.2 KRT20 KRT7
15 jejunal adenocarcinoma 10.2 KRT20 KRT7
16 ovarian mucinous adenocarcinoma 10.2 KRT20 KRT7
17 mucinous adenocarcinoma 10.2 KRT20 KRT7
18 thymus adenocarcinoma 10.2 KRT20 KRT7
19 appendix disease 10.2 KRT20 KRT7
20 meibomian cyst 10.2 KRT20 KRT7
21 bladder lymphoma 10.2 KRT20 KRT7
22 papillary serous adenocarcinoma 10.2 KRT20 KRT7
23 chronic cystitis 10.2 KRT20 KRT7
24 medulloepithelioma 10.2 KRT20 KRT7
25 glycogen-rich clear cell breast carcinoma 10.2 KRT20 KRT7
26 rectum adenocarcinoma 10.2 KRT20 KRT7
27 renal pelvis carcinoma 10.2 KRT20 KRT7
28 mucinous bronchioloalveolar adenocarcinoma 10.2 KRT20 KRT7
29 ampulla of vater adenocarcinoma 10.2 KRT20 KRT7
30 biliary papillomatosis 10.2 KRT20 KRT7
31 endocervical adenocarcinoma 10.2 KRT20 KRT7
32 cervical adenocarcinoma 10.2 KRT20 KRT7
33 eccrine sweat gland neoplasm 10.2 KRT20 KRT7
34 dermoid cyst 10.2 KRT20 KRT7
35 large cell acanthoma 10.2 KRT7 MTOR
36 cystadenofibroma 10.2 KRT20 KRT7
37 ovarian mucinous neoplasm 10.2 KRT20 KRT7
38 thymus lipoma 10.2 KRT20 KRT7
39 mucinous cystadenocarcinoma 10.2 KRT20 KRT7
40 appendix cancer 10.2 KRT20 KRT7
41 prostatic acinar adenocarcinoma 10.2 KRT20 KRT7
42 immune system organ benign neoplasm 10.2 KRT20 KRT7
43 cystic teratoma 10.2 KRT20 KRT7
44 morpheaform basal cell carcinoma 10.2 CDH1 KRT20
45 ovarian cystic teratoma 10.2 KRT20 KRT7
46 pancreatic mucinous cystadenoma 10.2 KRT20 KRT7
47 cystadenoma 10.2 KRT20 KRT7
48 horseshoe kidney 10.2 KRT20 KRT7
49 clear cell adenofibroma 10.2 KRT7 MTOR
50 renal pelvis adenocarcinoma 10.2 CDH1 KRT7

Graphical network of the top 20 diseases related to Large Intestine Adenocarcinoma:



Diseases related to Large Intestine Adenocarcinoma

Symptoms & Phenotypes for Large Intestine Adenocarcinoma

GenomeRNAi Phenotypes related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.02 CDH1 EIF4EBP1 KRT7 MCM3 MTOR

MGI Mouse Phenotypes related to Large Intestine Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.17 CDH1 CTNNB1 EIF4EBP1 KRT7 MCM3 MTOR

Drugs & Therapeutics for Large Intestine Adenocarcinoma

Drugs for Large Intestine Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4 7439-89-6 23925
2 Ferric Compounds Phase 4
3 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
4 Hepcidins Phase 4
5 Iron Supplement Phase 4
6
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
8
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
9
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
10
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
11
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
12
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
13
Atezolizumab Approved, Investigational Phase 3,Phase 2 1380723-44-3
14
Nicotine Approved Phase 3 54-11-5 942 89594
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
16
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
17 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
18 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
19 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
20 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
21 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Calcium, Dietary Phase 3,Phase 2
25 Antidotes Phase 3,Phase 2,Phase 1,Not Applicable
26 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
27 Antibodies Phase 3,Phase 2,Phase 1
28 Immunoglobulins Phase 3,Phase 2,Phase 1
29 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
30 Pharmaceutical Solutions Phase 3,Phase 2
31 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
33 Vitamins Phase 3,Phase 2,Phase 1,Not Applicable
34 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
35 Folate Phase 3,Phase 2,Phase 1,Not Applicable
36 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
37 Bone Density Conservation Agents Phase 3,Phase 2
38 Immunoglobulin G Phase 3,Phase 2
39 Endothelial Growth Factors Phase 3,Phase 2
40 Mitogens Phase 3,Phase 2,Phase 1
41 Tetrahydrofolates Phase 3
42 Formyltetrahydrofolates Phase 3
43 Mitomycins Phase 2, Phase 3
44
s 1 (combination) Phase 3
45
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
46
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
47
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
48
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
49
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
50
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631

Interventional clinical trials:

(show top 50) (show all 133)
# Name Status NCT ID Phase Drugs
1 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
2 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
3 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) Completed NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
4 Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases Completed NCT00265356 Phase 3
5 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
6 Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM Recruiting NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
7 Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Recruiting NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
8 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Recruiting NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
9 Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases Recruiting NCT02758951 Phase 2, Phase 3
10 Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT) Active, not recruiting NCT02390947 Phase 3 Famitinib;Placebo
11 Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma Not yet recruiting NCT03708536 Phase 3 S-1;Bevacizumab;Capecitabine
12 TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases) Not yet recruiting NCT03783559 Phase 3 TACE;chemotherapy±target therapy
13 Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
14 Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma . Unknown status NCT02788006 Phase 2 Regorafenib 160 mg
15 Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
16 Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma Unknown status NCT00075556 Phase 2 capecitabine
17 Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
18 Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Unknown status NCT00104689 Phase 2 capecitabine;oxaliplatin
19 Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
20 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
21 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
22 Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
23 Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
24 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma Completed NCT00574171 Phase 2 lapatinib;Capecitabine
25 Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma Completed NCT01479465 Phase 2 Simtuzumab;FOLFIRI;Placebo to match simtuzumab
26 DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT00080834 Phase 2 DJ-927
27 Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy Completed NCT00419159 Phase 2 Everolimus (RAD001)
28 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus
29 Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
30 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
31 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed NCT00582660 Phase 2 Celecoxib;Placebo
32 Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer Completed NCT00003220 Phase 2 bryostatin 1
33 Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer Completed NCT00025350 Phase 2 gefitinib
34 Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Completed NCT00890305 Phase 2 CT-011;FOLFOX
35 Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver Completed NCT00149396 Phase 1, Phase 2 NV1020
36 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer Completed NCT01417494 Phase 2 Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
37 Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer Completed NCT00123851 Phase 2 Tarceva (OSI-774);Capecitabine;Oxaliplatin
38 Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy Completed NCT01225744 Phase 2 Cetuximab;Irinotecan;Oxaliplatin;UFT
39 Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed Completed NCT00259844 Phase 2
40 Azacitidine and CAPOX in Metastatic Colorectal Cancer Completed NCT01193517 Phase 1, Phase 2 Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
41 Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma Recruiting NCT01844076 Phase 1, Phase 2 Phase I (Quinacrine);Capecitabine
42 Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Recruiting NCT03559543 Phase 2
43 Chemotherapy and/or Metastasectomy in Treating Participants With Metastatic Colorectal Adenocarcinoma With Lung Metastases Recruiting NCT03599752 Phase 2 Chemotherapy
44 FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation Recruiting NCT03584711 Phase 2
45 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
46 Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Recruiting NCT03642067 Phase 2 Nivolumab;Relatlimab
47 Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver Recruiting NCT03069950 Phase 2 Floxuridine (FUDR);Irinotecan (CPT-11);FLUOROURACIL;PANITUMUMAB;DEXAMETHASONE;Leucovorin
48 Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA) Recruiting NCT02738606 Phase 2 Chemotherapy
49 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Recruiting NCT03442569 Phase 2 Panitumumab;Nivolumab;Ipilimumab
50 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer Recruiting NCT01053013 Phase 2

Search NIH Clinical Center for Large Intestine Adenocarcinoma

Genetic Tests for Large Intestine Adenocarcinoma

Anatomical Context for Large Intestine Adenocarcinoma

MalaCards organs/tissues related to Large Intestine Adenocarcinoma:

41
Lung, Kidney, Colon, Tongue, Ovary, Thymus, Appendix

Publications for Large Intestine Adenocarcinoma

Variations for Large Intestine Adenocarcinoma

Expression for Large Intestine Adenocarcinoma

Search GEO for disease gene expression data for Large Intestine Adenocarcinoma.

Pathways for Large Intestine Adenocarcinoma

Pathways related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.45 CDH1 CTNNB1 EIF4EBP1 MTOR
2
Show member pathways
12.25 CDH1 CTNNB1 MTOR
3 12.23 CDH1 KRT20 KRT7
4 11.69 CDH1 CTNNB1 MTOR
5
Show member pathways
11.6 CTNNB1 EIF4EBP1 MTOR
6
Show member pathways
11.55 CDH1 CTNNB1 EIF4EBP1 MTOR
7 11.49 CTNNB1 EIF4EBP1 MTOR
8 11.34 EIF4EBP1 MTOR
9 11.32 CTNNB1 MTOR
10 11.25 EIF4EBP1 MTOR
11 11.2 CDH1 CTNNB1
12 11.15 CDH1 CTNNB1
13 11.14 CDH1 CTNNB1
14 11.06 EIF4EBP1 MTOR
15 11.03 CDH1 CTNNB1
16 10.97 CTNNB1 MTOR
17 10.95 EIF4EBP1 MTOR
18 10.89 EIF4EBP1 MTOR
19 10.83 CDH1 CTNNB1
20 10.62 EIF4EBP1 MTOR
21 10.07 CDH1 CTNNB1

GO Terms for Large Intestine Adenocarcinoma

Cellular components related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 9.16 CDH1 CTNNB1
2 apical junction complex GO:0043296 8.96 CDH1 CTNNB1
3 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Large Intestine Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of epithelial to mesenchymal transition GO:0010718 9.4 CTNNB1 MTOR
2 adherens junction organization GO:0034332 9.37 CDH1 CTNNB1
3 regulation of myelination GO:0031641 9.32 CTNNB1 MTOR
4 TOR signaling GO:0031929 9.26 EIF4EBP1 MTOR
5 regulation of osteoclast differentiation GO:0045670 9.16 CTNNB1 MTOR
6 entry of bacterium into host cell GO:0035635 8.96 CDH1 CTNNB1
7 cellular response to indole-3-methanol GO:0071681 8.62 CDH1 CTNNB1

Sources for Large Intestine Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....